DMetrix, Inc. and Definiens AG sign partnership to develop automated
digital pathology system
1 December 2006 Tucson, Ariz. & Munich, Germany. DMetrix, Inc.,
manufacturer of ultra-rapid, array-microscope digital imaging systems, has
entered into a partnership with Definiens AG, an enterprise image
intelligence company. The aim of the partnership is to accelerate the
development of a complete solution for automated digital pathology,
involving the image capture-to-analysis process in drug discovery. The
solution includes the DMetrix award-winning DX-40 array-microscope whole
slide scanner that captures images of slides in less than one minute as well
as the Definiens Enterprise Image Intelligence suite of products for a
powerful, accurate and automated analysis of captured images. While the
pharmaceutical industry worldwide struggles with a shortage of pathologists,
the volume of diagnostic testing for new drug development has expanded. This
increase in workload has multiplied the need for innovations that improve
productivity and testing accuracy. The DMetrix and Definiens partnership
which combines both platforms provides the far-reaching results that the
industry requires: a high throughput, ultra-rapid quantitative and objective
tool for preclinical research to speed the development process for new
therapeutics. Rodger Brown, Vice President of Sales and Marketing at
DMetrix, said, “The partnership with Definiens allows us to provide a
comprehensive solution to customers wanting to take advantage of the
conversion of raw digital pathological data into usable, well-defined
scientific information. By combining the leading Enterprise Image
Intelligence platform and DMetrix’s image capture instruments, we are
providing an innovative system that will enhance and expedite the way
preclinical studies are performed.” “The partnership with DMetrix brings
enormous value to our existing and future customers in the pharmaceutical
industry by increasing their insight into images,” said Rene Hermes,
Definiens Vice President of Marketing. “Definiens is committed to
continuously bring its capabilities to market, providing organizations with
complete solutions and expertise that support, accelerate and enhance all
phases of the drug development lifecycle.” To top
|
|